LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Sold by Riverwater Partners LLC

Riverwater Partners LLC lessened its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 2.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 30,776 shares of the medical instruments supplier’s stock after selling 925 shares during the period. LeMaitre Vascular comprises 1.4% of Riverwater Partners LLC’s portfolio, making the stock its 12th largest position. Riverwater Partners LLC’s holdings in LeMaitre Vascular were worth $2,836,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in LMAT. New York State Teachers Retirement System lifted its stake in LeMaitre Vascular by 1.2% during the fourth quarter. New York State Teachers Retirement System now owns 8,189 shares of the medical instruments supplier’s stock worth $755,000 after purchasing an additional 100 shares during the last quarter. Flputnam Investment Management Co. boosted its holdings in shares of LeMaitre Vascular by 3.6% in the 4th quarter. Flputnam Investment Management Co. now owns 2,923 shares of the medical instruments supplier’s stock valued at $269,000 after buying an additional 102 shares during the period. Norden Group LLC grew its position in shares of LeMaitre Vascular by 4.5% during the 4th quarter. Norden Group LLC now owns 2,371 shares of the medical instruments supplier’s stock valued at $218,000 after buying an additional 103 shares during the last quarter. Blue Barn Wealth LLC raised its stake in LeMaitre Vascular by 4.4% during the fourth quarter. Blue Barn Wealth LLC now owns 2,485 shares of the medical instruments supplier’s stock worth $229,000 after acquiring an additional 104 shares during the period. Finally, Shaker Investments LLC OH lifted its holdings in LeMaitre Vascular by 0.8% in the fourth quarter. Shaker Investments LLC OH now owns 13,948 shares of the medical instruments supplier’s stock worth $1,285,000 after acquiring an additional 112 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Trading Down 2.5 %

LMAT stock opened at $79.78 on Friday. The firm’s 50-day moving average is $91.62 and its two-hundred day moving average is $94.15. The company has a market capitalization of $1.80 billion, a price-to-earnings ratio of 43.60, a price-to-earnings-growth ratio of 2.22 and a beta of 0.89. LeMaitre Vascular, Inc. has a 52 week low of $62.39 and a 52 week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.49. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The firm had revenue of $55.81 million during the quarter, compared to the consensus estimate of $55.99 million. On average, equities research analysts predict that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 27th. Investors of record on Thursday, March 13th were issued a dividend of $0.20 per share. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.16. This represents a $0.80 dividend on an annualized basis and a yield of 1.00%. The ex-dividend date was Thursday, March 13th. LeMaitre Vascular’s payout ratio is presently 41.24%.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on LMAT shares. Wells Fargo & Company initiated coverage on LeMaitre Vascular in a report on Thursday, February 13th. They set an “equal weight” rating and a $95.00 target price for the company. Barrington Research downgraded LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Lake Street Capital raised their target price on LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Oppenheimer lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Finally, StockNews.com downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Five analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, LeMaitre Vascular has an average rating of “Moderate Buy” and an average target price of $95.25.

Insiders Place Their Bets

In other news, insider Trent G. Kamke sold 2,009 shares of LeMaitre Vascular stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total value of $164,979.08. Following the transaction, the insider now owns 5,564 shares of the company’s stock, valued at $456,915.68. The trade was a 26.53 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 10.79% of the stock is owned by company insiders.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.